Intelligent Systems Software in Boca Raton, FL, announced Jan. 17 that the FDA had cleared its computer-aided detection (CAD) system, MammoReader. The product is designed to help
Intelligent Systems Software in Boca Raton, FL, announced Jan. 17 that the FDA had cleared its computer-aided detection (CAD) system, MammoReader. The product is designed to help in early detection of breast cancer by increasing the detection of subtle signs of cancer. The system is cleared for both screening and diagnostic use. Supporting the company's FDA application were clinical data from 327 cancer cases, which showed that breast cancer in 23% of the women diagnosed with the disease could have been discovered an average of 14 months earlier on screening mammograms, if MammoReader had been used, according to the company. MammoReader analyses are based on digitized mammograms. The systems, which will be marketed by Instrumentarium, will be priced at $99,500 and up.
Study: AI Boosts Ultrasound AUC for Predicting Thyroid Malignancy Risk by 34 Percent Over TI-RADS
February 17th 2025In a study involving assessment of over 1,000 thyroid nodules, researchers found the machine learning model led to substantial increases in sensitivity and specificity for estimating the risk of thyroid malignancy over traditional TI-RADS and guidelines from the American Thyroid Association.
Can CT-Based AI Provide Automated Detection of Colorectal Cancer?
February 14th 2025For the assessment of contrast-enhanced abdominopelvic CT exams, an artificial intelligence model demonstrated equivalent or better sensitivity than radiologist readers, and greater than 90 percent specificity for the diagnosis of colorectal cancer.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.